Join
Live feed
·
PRReleasevia Quantisnow
Corbus Pharmaceuticals Holdings Inc. logo

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

ByQuantisnow·Wall Street's wire, on your screen.
CRBP· Corbus Pharmaceuticals Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRBP (Corbus Pharmaceuticals Holdings Inc.) and more on Quantisnow.

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss | Quantisnow